3-methyl-2-(4-oxo-2-thioxothiazolidin-3-yl)butanoic acid | 6593-95-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-methyl-2-(4-oxo-2-thioxothiazolidin-3-yl)butanoic acid
• 英文别名: 3-Methyl-2-(4-oxo-2-thioxo-thiazolidin-3-yl)-butyric acid；3-methyl-2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)butanoic acid
• CAS: 6593-95-9
• 化学式: C₈H₁₁NO₃S₂
• mdl: MFCD00457542
• 分子量: 233.312
• InChiKey: CAFMKIQOSYUXLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-methyl-2-(4-oxo-2-thioxothiazolidin-3-yl)butanoic acid 在 氯化亚砜 、 sodium acetate 、 三乙胺 作用下， 以 1,4-二氧六环 、 溶剂黄146 、 甲苯 为溶剂， 反应 2.17h， 生成 2-[(5Z)-5-(4-bromobenzylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methyl-N-[3-(morpholin-4-yl)propyl]butanamide
  参考文献：
  名称：

  Synthesis, Physicochemical Properties, Drug Likeness, and Antitumor Activity of 2-[5-(4-Bromobenzylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-methylbutanoic Acid Esters and Amides

  摘要：

  DOI：

  10.1134/s1070428021010048
• 作为产物：
  描述：

  2-(Dithiocarboxyamino)-3-methylbutanoic acid 在 盐酸 作用下， 以 水 为溶剂， 反应 15.0h， 生成 3-methyl-2-(4-oxo-2-thioxothiazolidin-3-yl)butanoic acid
  参考文献：
  名称：

  Optimization of rhodanine scaffold for the development of protein–protein interaction inhibitors

  摘要：

  Searching for novel protein-protein interactions inhibitors (PPIs) herein we describe the identification of a new series of rhodanine derivatives. The selection was performed by means virtual-screening, docking studies, Molecular Dynamic (MD) simulations and synthetic approaches. All the new obtained compounds were tested in order to evaluate their ability to inhibit the interaction between the HIV-1 integrase (IN) enzyme and the nuclear protein lens epithelium growth factor LEDGF/p75. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.072

文献信息

• In Silico Driven Design and Synthesis of Rhodanine Derivatives as Novel Antibacterials Targeting the Enoyl Reductase InhA
  作者：Liudas Slepikas、Gianpaolo Chiriano、Remo Perozzo、Sébastien Tardy、Agata Kranjc、Ophélie Patthey-Vuadens、Hajer Ouertatani-Sakouhi、Sébastien Kicka、Christopher F. Harrison、Tiziana Scrignari、Karl Perron、Hubert Hilbi、Thierry Soldati、Pierre Cosson、Eduardas Tarasevicius、Leonardo Scapozza

  DOI：10.1021/acs.jmedchem.5b01620

  日期：2016.12.22

  computational studies. Their antimicrobial activity was assessed against Mycobacterium marinum (Mm) (a model for Mtb), Pseudomonas aeruginosa (Pa), Legionella pneumophila (Lp), and Enterococcus faecalis (Ef) by using anti-infective, antivirulence, and antibiotic assays. Nineteen out of 34 compounds reduced Mm virulence at 10 μM. 33 exhibited promising antibiotic activity against Mm with a MIC of 0.21 μM and showed

  在这里，我们报告针对结核分枝杆菌结核（Mtb）反-2-烯酰基酰基载体蛋白还原酶（InhA）的4-噻唑烷酮（若丹宁）衍生物的设计，合成和生物学评估。在罗丹宁环第5位具有庞大芳族取代基且在N -3位具有色氨酸残基的化合物对InhA的活性最高，IC 50值为2.7至30μM。实验数据显示与计算研究一致的相关性。他们的抗菌活性评估了对结核分枝杆菌（Mm）（铜绿假单胞菌（Mtb）的模型）。Pa），嗜肺军团菌（Lp）和粪肠球菌（Ef），方法是使用抗感染，抗毒力和抗生素检测方法。34种化合物中有19种降低了10μM的Mm毒力。33的MIC为0.21μM，对Mm表现出有希望的抗生素活性，在30μM的抗感染试验中，Lp的生长降低了89％。32显示对Ef的高抗生素活性，MIC为0.57μM。
• [EN] BIARYLRHODANINE AND PYRIDYLRHODANINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE BIARYLRHODANINE ET DE PYRIDYLRHODANINE ET LEUR UTILISATION
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2010024783A1

  公开（公告）日：2010-03-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to compounds related to rhodanine, which compounds are inter alia inhibitors and/or binders of antiapoptotic/pro-survival Bcl-2 proteins such as Bcl-XL and/or Mcl-1. More specifically, the present invention is concerned with Rhodanine- based Pan-Bcl-2 inhibitors and Mcl-1 -specific inhibitors as anti-cancer compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit and/or bind Bcl-2 proteins such as Bcl-XL and/or Mcl-1, and in the treatment of diseases and conditions that are mediated by Bcl-2 proteins, that are ameliorated by the inhibition of Bcl-2 protein function (such as Bcl-XL and/or Mcl-1 ) including proliferative conditions such as cancer, optionally in combination with another agent.

  本发明一般涉及治疗化合物领域，更具体地涉及与罗丹宁相关的化合物，这些化合物是抑制剂和/或结合剂，用于抑制和/或结合抗凋亡/促存活的Bcl-2蛋白，如Bcl-XL和/或Mcl-1。更具体地，本发明涉及基于罗丹宁的Pan-Bcl-2抑制剂和Mcl-1特异性抑制剂作为抗癌化合物。本发明还涉及包括这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制和/或结合Bcl-2蛋白，如Bcl-XL和/或Mcl-1，并用于治疗由Bcl-2蛋白介导的疾病和症状，通过抑制Bcl-2蛋白功能（如Bcl-XL和/或Mcl-1）改善的疾病和症状，包括增殖性疾病如癌症，可选择地与另一药剂联合使用。
• Synthesis and Bioactivity Evaluation of N-Arylsulfonylindole Analogs Bearing a Rhodanine Moiety as Antibacterial Agents
  作者：Ming-Xia Song、Song-Hui Li、Jiao-Yang Peng、Ting-Ting Guo、Wen-Hui Xu、Shao-Feng Xiong、Xian-Qing Deng

  DOI：10.3390/molecules22060970

  日期：——

  the scarcity of novel agents under development, bacterial infections are still a pressing global problem, making new types of antibacterial agents, which are effective both alone and in combination with traditional antibiotics, urgently needed. In this paper, seven series of N-arylsulfonylindole analogs 5–11 bearing rhodanine moieties were synthesized, characterized, and evaluated for antibacterial

  由于细菌对抗生素的耐药性迅速增长，并且正在开发的新型药物的稀缺性，细菌感染仍然是一个紧迫的全球问题，迫切需要新型抗菌药物，无论是单独使用还是与传统抗生素联合使用都有效。在本文中，合成、表征和评估了七个系列的 N-芳基磺酰基吲哚类似物 5-11 带有罗丹宁部分的抗菌活性。根据体外抗菌结果，一半合成的化合物对四种革兰氏阳性菌显示出有效的抑制作用，MIC 值在 0.5-8 µg/mL 范围内。对于多重耐药菌株，化合物 6a 和 6c 的效力最强，MIC 值为 0.5 µg/mL，与加替沙星的活性相当，
• Synthesis, antiproliferative activity and docking study of novel rhodanine derivatives as Bcr-Abl T1351 inhibitors
  作者：Sulaiman Ali Muhammad、Subban Ravi、Arumugam Thangamani、Balakumar Chandrasekaran、M. Ramesh

  DOI：10.1007/s11164-017-2968-6

  日期：2017.10

  A series of novel N -substituted rhodanines 6a–g were synthesized by a microwave synthesizer, and evaluated for their anti-proliferative activity. Most of the compounds showed inhibition against K562 cells in a dose-dependent manner and in particular compounds 6a , 6b and 6f exhibited most potent activity with an IC50 value of 19.62, 24.01 and 22.91 µg/ml by MTT assay. Further in silico docking studies

  用微波合成仪合成了一系列新型的 N- 取代的罗丹 酮6a-g ，并评估了它们的抗增殖活性。大多数化合物显示出对K562细胞的抑制作用，呈剂量依赖性，特别是化合物 6a ， 6b 和 6f 表现出最强的活性，通过MTT分析，IC 50值为19.62、24.01和22.91 µg / ml。上述化合物对Bcr-Abl T1351蛋白的进一步计算机对接研究显示出良好的结合亲和力，因此表明该化合物表现为第三代抑制剂。用 6a–g 治疗后，LDH释放的剂量依赖性增加 补充了MTT分析的抗增殖活性。 6a的 流式细胞术 显示它通过指示G1期阻滞然后凋亡来干扰细胞分裂。
• Novel phenothiazine-based chalcone derivatives with various N-substituted rhodanines induce growth inhibition followed by apoptosis in leukemia cells
  作者：Sulaiman Ali Muhammad、Arumgam Thangamani、Subban Ravi

  DOI：10.1007/s11164-017-2953-0

  日期：2017.10

  Eight new series of novel phenothiazine-based chalcone derivatives with various N-substituted rhodanines ( 10a – g to 17a – g ) were synthesized by microwave-assisted synthesis and tested for their chemotherapeutic properties. The results show that compounds 15g and 14e induced cytotoxicity in a time- and concentration-dependent manner in leukemia cell line K562. Among the compounds tested, 15g and

  通过微波辅助合成法合成了八种新的新颖的基于吩噻嗪的新型查尔酮衍生物，其具有各种N-取代的罗丹酮（ 10a - g 至 17a - g ），并对其化学治疗性能进行了测试。结果表明，化合物 15g 和 14e 在时间和浓度上对白血病细胞K562诱导细胞毒性。在测试的化合物中， 通过锥虫蓝测定法在抑制浓度为50％的条件下，发现 15g 和 14e 更有效（IC 50）值分别为14.48和14.73 µg / ml，3-（4,5-二甲基噻唑-2-基）-2,5-二苯基四唑溴化物（MTT）测定的IC 50值分别为12.85和13.53 µg / ml。这些化合物的抗增殖活性已通过乳酸脱氢酶（LDH）分析进一步证实。 15g 和 14e 对白血病细胞的抗增殖作用 主要归因于凋亡的诱导。还研究了合成化合物的结构-活性关系。分子对接研究表明，这些化合物可能充当第三代T315I突变的Bcr-Abl激酶抑制剂。